Pilot Study: FSHR Expression in Neuroendocrine Tumors of the Appendix.
ANEN
FSHR
appendix neuroendocrine neoplasm
endothelial cells
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
23
05
2023
revised:
27
07
2023
accepted:
30
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Appendix neuroendocrine neoplasm (ANEN) treatment is based on tumor size and proliferation markers. Recently, the role of the follicle-stimulating hormone receptor (FSHR) from the clinical perspective has also been increasingly discussed. The FSHR is expressed in the endothelial cells of both intratumoral and peritumoral blood vessels, where it contributes to neoangiogenesis and blood vessel remodeling. FSHR expression is associated with a range of tumor types, such as gastrointestinal tumors, and it is not detected in healthy tissues located more than 10 mm from the tumor site or in tumor lymphatics. In this study, we evaluated the expression of FSHR and CD31 in the blood vessels of ANENs in females and males with confirmed histopathology. We conducted a quantitative analysis of the immunohistochemical reactions and found a higher number of microvessels in the mucosa and submucosa of neuroendocrine tumors in the appendix. A higher level of FSHR expression was observed in women. Future research should consider whether an elevated number of blood vessels along with a strong pattern of FSHR expression may influence future treatment strategies.
Identifiants
pubmed: 37568488
pii: jcm12155086
doi: 10.3390/jcm12155086
pmc: PMC10419379
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
World J Gastroenterol. 2020 May 21;26(19):2305-2322
pubmed: 32476795
Neuroendocrinology. 2016;103(2):144-52
pubmed: 26730583
J Nucl Med. 2010 May;51(5):669-73
pubmed: 20395323
N Engl J Med. 2010 Oct 21;363(17):1621-30
pubmed: 20961245
Dig Liver Dis. 2014 Jan;46(1):9-17
pubmed: 23731843
J Natl Cancer Inst. 2002 Jun 19;94(12):883-93
pubmed: 12072542
J Cell Mol Med. 2012 Sep;16(9):2010-6
pubmed: 22129368
Endokrynol Pol. 2014;65(6):469-71
pubmed: 25554615
Surgery. 2022 Oct;172(4):1236-1244
pubmed: 35953308
J Ovarian Res. 2020 Apr 17;13(1):39
pubmed: 32303227
PLoS One. 2018 Mar 1;13(3):e0189337
pubmed: 29494614
J Ovarian Res. 2013 Jul 20;6:52
pubmed: 23870332
Stem Cells Dev. 2011 Aug;20(8):1451-64
pubmed: 21291304
J Ovarian Res. 2021 Oct 30;14(1):144
pubmed: 34717708
Pediatr Dev Pathol. 2023 May-Jun;26(3):250-258
pubmed: 37334832
Foods. 2022 Feb 25;11(5):
pubmed: 35267318
Mol Pharm. 2015 Feb 2;12(2):403-10
pubmed: 25581441
BMC Cancer. 2013 May 20;13:246
pubmed: 23688201
Ann Gastroenterol. 2021 Sep-Oct;34(5):713-720
pubmed: 34475743
Hum Pathol. 2014 Apr;45(4):866-74
pubmed: 24656098
J Ovarian Res. 2021 Oct 30;14(1):145
pubmed: 34717703
Pancreas. 2010 Aug;39(6):713-34
pubmed: 20664471
Endokrynol Pol. 2013;64(4):268-71
pubmed: 24002953
Neuroendocrinology. 2013;97(1):45-56
pubmed: 22538258
J Ovarian Res. 2018 Jan 5;11(1):3
pubmed: 29304868
Endokrynol Pol. 2012;63(6):477-82
pubmed: 23339006
Endocrinology. 2018 Sep 1;159(9):3268-3274
pubmed: 30113652
Lancet Oncol. 2023 Feb;24(2):187-194
pubmed: 36640790
J Endocrinol Invest. 2013 Mar;36(3):174-9
pubmed: 22732316
Br J Surg. 2003 Nov;90(11):1317-22
pubmed: 14598408
Endocr Relat Cancer. 2019 Jan 1;26(1):103-117
pubmed: 30400009
Endocr Relat Cancer. 2016 Jan;23(1):R27-41
pubmed: 26483424
Cancers (Basel). 2022 Dec 31;15(1):
pubmed: 36612291
Endokrynol Pol. 2017;68(2):79-110
pubmed: 28597909
Mol Imaging Biol. 2014 Aug;16(4):578-85
pubmed: 24389931
Neuroendocrinology. 2018;106(3):242-251
pubmed: 28641291
Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):729-38
pubmed: 16253897
Anticancer Res. 2018 Feb;38(2):601-611
pubmed: 29374682
Mol Diagn Ther. 2016 Dec;20(6):523-530
pubmed: 27392476
Mol Imaging Biol. 2014 Feb;16(1):1-9
pubmed: 24037176
Sci Rep. 2016 Nov 16;6:37095
pubmed: 27848975